Evidence map›Paper›PMID 37274066›Full record

ArticleWorld journal of gastroenterology2023

Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases.

Heinrich Steinhoff, Miklos Acs, Sebastian Blaj, Magdolna Dank, Magdolna Herold, Zoltan Herold, Jonas Herzberg, Patricia Sanchez-Velazquez, Tim Strate, Attila Marcell Szasz and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Heinrich SteinhoffDepartment of General and Visceral Surgery, Hospital Barmherzige Brüder, Regensburg 93049, Germany. heinrich.steinhoff@barmherzige-regensburg.de.
Miklos AcsDepartment of General and Visceral Surgery, Hospital Barmherzige Brüder, Regensburg 93049, Germany.
Sebastian BlajDepartment of General and Visceral Surgery, Hospital Barmherzige Brüder, Regensburg 93049, Germany.
Magdolna DankDivision of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest 1083, Hungary.
Magdolna HeroldDepartment of Internal Medicine and Hematology, Semmelweis University, Budapest 1088, Hungary.
Zoltan HeroldDivision of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest 1083, Hungary.
Jonas HerzbergDepartment of Surgery, Krankenhaus Reinbek St. Adolf-Stift, Reinbek 21465, Germany.
Patricia Sanchez-VelazquezDepartment of General Surgery, Hospital del Mar, Barcelona 08003, Spain.
Tim StrateDepartment of Surgery, Krankenhaus Reinbek St. Adolf-Stift, Reinbek 21465, Germany.
Attila Marcell SzaszDivision of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest 1083, Hungary.
Pompiliu PisoDepartment of General and Visceral Surgery, Hospital Barmherzige Brüder, Regensburg 93049, Germany.
Krankenhaus Barmherzige Brüder · DESemmelweis University · HUKrankenhaus Reinbek - Startseite · DEHospital Del Mar · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdvanced gastric cancer with synchronous peritoneal metastases (GC-PM) is associated with a poor prognosis. Although cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a promising approach, only a limited number of Western studies exist.

aimTo investigate the clinicopathological outcomes of patients who underwent CRS-HIPEC for GC-PM.

methodsA retrospective analysis of patients with GC-PM was conducted. All patients were seen at the Department of General and Visceral Surgery, Hospital Barmherzige Brüder, Regensburg, Germany between January 2011 and July 2021 and underwent CRS-HIPEC. Preoperative laboratory results, the use of neoadjuvant trastuzumab, and the details of CRS-HIPEC, including peritoneal carcinomatosis index, completeness of cytoreduction, and surgical procedures were recorded. Disease-specific (DSS), and overall survival (OS) of patients were calculated.

resultsA total of 73 patients were included in the study. Patients treated with neoadjuvant trastuzumab (

conclusionBased on our experience, CRS-HIPEC is a safe and secure method to improve the survival of advanced GC-PM patients. Prolonged HIPEC duration may serve as a good therapy for these patients.

Indexed as

Hyperthermia, InducedPeritoneal NeoplasmsStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCisplatinCombined Modality TherapyCytoreduction Surgical ProceduresHumansHyperthermic Intraperitoneal ChemotherapyRetrospective StudiesSurvival RateTrastuzumabCisplatinTrastuzumabCytoreductive surgeryGastric cancerHyperthermic intraperitoneal chemotherapyPeritoneal metastasisStomach neoplasms

Identifiers

PMID37274066
PMCPMC10237111
OpenAlexW4376120000

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.